Comprehensive evaluation of Impella RP ® in right ventricular failure.
Andrea MontisciSilvia SalaGiulia MajSergio CattaneoFederico PappalardoPublished in: Future cardiology (2022)
Right ventricular failure has a high morbidity and mortality in patients suffering from advanced heart failure, pulmonary hypertension, acute myocardial infarction after cardiac surgery and in left ventricular assist device patients. The Impella RP ® catheter is a mechanical circulatory device, positioned from a venous femoral percutaneous access and passing through the tricuspid and pulmonary valves, reaches the pulmonary artery. Impella RP (Abiomed Inc., MA, USA) acts as a direct right ventricle bypass and it provides a flow up to 4.4 liters per minute, unloading the right ventricle. The main contraindications are: thrombi in the vena cava, right atrium and ventricle and pulmonary artery; mechanical tricuspid or pulmonary prostheses. In this review, the principles of operations, clinical applications and results of Impella RP are summarized and evaluated.
Keyphrases
- pulmonary artery
- pulmonary hypertension
- pulmonary arterial hypertension
- coronary artery
- left ventricular assist device
- end stage renal disease
- heart failure
- acute myocardial infarction
- ejection fraction
- vena cava
- chronic kidney disease
- aortic valve
- mitral valve
- extracorporeal membrane oxygenation
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- coronary artery disease
- minimally invasive
- inferior vena cava
- acute coronary syndrome
- ultrasound guided
- transcatheter aortic valve replacement
- patient reported
- left ventricular